ClinicalTrials.gg
CompletedNCT02225587Updated Nov 2, 2021Results posted

Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)

A Phase 3 interventional study of Prevnar 13™ and Pneumovax™ 23 in Pneumococcal Infections, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
17th of 44
400 · median 328
Started
2014
with 1 other
Phase 3
19 of 44
none open now
Registered
24th of 44
by date
Lead sponsor
2 of 44
Merck Sharp & Dohme LLC

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 17th largest by enrollment, is one of 2 that started in 2014, is one of 19 in phase 3, and was the 24th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of sequential administration of Prevnar 13™ and Pneumovax™ 23 in healthy participants 50 years of age and older. The primary hypotheses in the study are that 1) geometric mean titers (GMTs) to pneumococcal serotypes 22F and 33F (serotypes in Pneumovax™ 23 but not in Prevnar 13™) as measured at Week 12 are superior in participants administered Prevnar 13™ on Day 1 and Pneumovax™ 23 at Week 8, as compared with participants administered Prevnar 13™ on Day 1 and placebo at Week 8 and 2) GMTs to pneumococcal serotypes shared by the two vaccines as measured at Week 12 are non-inferior in participants administered Prevnar 13™ followed by Pneumovax™ 23 as compared with participants administered Prevnar 13™ followed by placebo.

03

Conditions studied

  • Pneumococcal Infections
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any chronic illness must be documented to be in stable condition
  • Male, or a female agrees to remain abstinent, or use, or have their partner use, 2 acceptable methods of through 6 weeks after receiving study vaccination; or a female who is not of

Exclusion criteria

Exclusion Criteria:

  • Is or has an immediate family member who is site or sponsor staff directly involved with this trial
  • Prior administration of any pneumococcal vaccine
  • History of invasive pneumococcal disease
  • Known to any component of the pneumococcal polysaccharide vaccine, of the pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine
  • Known or suspected impairment of immunological function, documented (HIV) infection, asplenia, or history of disease
  • Received systemic (equivalent of >=2 mg/kg total daily dose of prednisone or >=20 mg/kg for persons weighing >10 kg) for >=14 consecutive days and has not completed treatment \<=30 days before study vaccination, or has received systemic corticosteroids exceeding physiological doses (\~5 mg/day prednisone equivalent) within 14 days before study vaccination (topical, ophthalmic, intra-articular, and inhaled/nebulized steroids are permitted).
  • Has a coagulation disorder contraindicating intramuscular vaccination
  • Receiving therapy, including chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation or autoimmune disease
  • Received a blood transfusion or blood products, including immunoglobulins \<=6 months before receiving study vaccine, or is scheduled to receive them within 30 days
  • Participated in another clinical study of an investigational product \<=2 months before or during the current study
  • Is breast-feeding
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo

    Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Pneumovax™ 23 0.5 mL intramuscular injection at Week 8, and Placebo 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.

    Biological: Prevnar 13™ · Biological: Pneumovax™ 23 · Biological: Placebo

  • Placebo comparator
    Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23

    Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Placebo 0.5 mL intramuscular injection at Week 8, and Pneumovax™ 23 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.

    Biological: Prevnar 13™ · Biological: Pneumovax™ 23 · Biological: Placebo

Interventions

  • BiologicalPrevnar 13™

    Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.

  • BiologicalPneumovax™ 23

    Drug page: 23-valent pneumococcal capsular polysaccharide vaccine

    Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.

  • BiologicalPlacebo

    Injections are to be administered into the deltoid muscle of the upper arm.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Adverse Event (AE)

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

    Time frame: Up to 14 days after any vaccination (Up to 28 weeks)

  2. Percentage of Participants With an Injection-site Adverse Event

    An injection site adverse event (AE) includes the following AEs at the injection site: redness, swelling, and pain/tenderness.

    Time frame: Up to 14 days after any vaccination (Up to 28 weeks)

  3. Percentage of Participants With a Systemic Adverse Event

    Systemic adverse events (AEs) include, but are not restricted to the following AE terms: muscle pain, joint pain, headache, and tiredness.

    Time frame: Up to 14 days after any vaccination (Up to 28 weeks)

  4. Percentage of Participants With a Serious Adverse Event (SAE)

    A serious adverse event (SAE) is any adverse event occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; or is associated with an overdose.

    Time frame: Up to 30 weeks

  5. Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE) or Vaccine-related Death

    A serious adverse event (SAE) is any adverse event occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; or is associated with an overdose. The investigator determined whether the SAE or death was related to vaccine treatment.

    Time frame: Up to 30 weeks

  6. Percentage of Participants Who Discontinued Vaccination Due to an Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

    Time frame: Up to 26 weeks

  7. Geometric Mean Titers to Pneumococcal Serotypes 22F and 33F at Week 12

    Vaccine-induced functional antibodies to serotypes 22F and 33F, which are unique to PNEUMOVAX™ 23, were measured by the multiplex opsonophagocytic activity 4 (MOPA-4) assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.

    Time frame: Week 12

  8. Geometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, at Week 12

    Vaccine-induced functional antibodies to serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, which are contained in both Prevnar 13™ and PNEUMOVAX™ 23, were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.

    Time frame: Week 12

Secondary outcomes

  1. Geometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F at Week 8

    Vaccine-induced functional antibodies were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.

    Time frame: Week 8

  2. Geometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F at Week 26

    Vaccine-induced functional antibodies were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.

    Time frame: Week 26

  3. Geometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F at Week 30

    Vaccine-induced functional antibodies were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.

    Time frame: Week 30

07

Results

Posted Feb 5, 2020

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23
Started200200
Vaccination 2188185
Vaccination 3172164
Completed172162
Not completed2838
Withdrew: Adverse event55
Withdrew: Lost to follow-up55
Withdrew: Non-compliance with study drug10
Withdrew: Physician decision20
Withdrew: Protocol violation10
Withdrew: Participant moved10
Withdrew: Withdrawal by subject1328

Outcome measures

PrimaryPercentage of Participants With an Adverse Event (AE)

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

Time frame:
Up to 14 days after any vaccination (Up to 28 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With an Adverse Event (AE)
Percentage of participantsGroup 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23
Percentage of Participants With an Adverse Event (AE)89.984.4
PrimaryPercentage of Participants With an Injection-site Adverse Event

An injection site adverse event (AE) includes the following AEs at the injection site: redness, swelling, and pain/tenderness.

Time frame:
Up to 14 days after any vaccination (Up to 28 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With an Injection-site Adverse Event
Percentage of participantsGroup 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23
Percentage of Participants With an Injection-site Adverse Event86.477.9
PrimaryPercentage of Participants With a Systemic Adverse Event

Systemic adverse events (AEs) include, but are not restricted to the following AE terms: muscle pain, joint pain, headache, and tiredness.

Time frame:
Up to 14 days after any vaccination (Up to 28 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With a Systemic Adverse Event
Percentage of participantsGroup 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23
Percentage of Participants With a Systemic Adverse Event76.874.4
PrimaryPercentage of Participants With a Serious Adverse Event (SAE)

A serious adverse event (SAE) is any adverse event occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; or is associated with an overdose.

Time frame:
Up to 30 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With a Serious Adverse Event (SAE)
Percentage of participantsGroup 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23
Percentage of Participants With a Serious Adverse Event (SAE)4.55.5
PrimaryPercentage of Participants With a Vaccine-related Serious Adverse Event (SAE) or Vaccine-related Death

A serious adverse event (SAE) is any adverse event occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; or is associated with an overdose. The investigator determined whether the SAE or death was related to vaccine treatment.

Time frame:
Up to 30 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE) or Vaccine-related Death
Percentage of participantsGroup 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23
Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE) or Vaccine-related Death00
PrimaryPercentage of Participants Who Discontinued Vaccination Due to an Adverse Event

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

Time frame:
Up to 26 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Vaccination Due to an Adverse Event
Percentage of participantsGroup 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23
Percentage of Participants Who Discontinued Vaccination Due to an Adverse Event2.52.5
PrimaryGeometric Mean Titers to Pneumococcal Serotypes 22F and 33F at Week 12

Vaccine-induced functional antibodies to serotypes 22F and 33F, which are unique to PNEUMOVAX™ 23, were measured by the multiplex opsonophagocytic activity 4 (MOPA-4) assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.

Time frame:
Week 12
Reported as:
Geometric mean · Titer
Geometric Mean Titers to Pneumococcal Serotypes 22F and 33F at Week 12
TiterGroup 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23
Serotype 22F1766.3 (1303.2 to 2394.1)39.0 (28.3 to 53.7)
Serotype 33F10413.0 (8178.9 to 13257.4)1189.9 (898.6 to 1575.6)
PrimaryGeometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, at Week 12

Vaccine-induced functional antibodies to serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, which are contained in both Prevnar 13™ and PNEUMOVAX™ 23, were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.

Time frame:
Week 12
Reported as:
Geometric mean · Titer
Geometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, at Week 12
TiterGroup 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23
Serotype 181.7 (60.4 to 110.7)57.1 (41.1 to 79.3)
Serotype 343.4 (33.7 to 55.9)17.5 (13.5 to 22.5)
Serotype 41079.3 (885.7 to 1315.2)780.0 (629.1 to 967.1)
Serotype 5198.6 (145.6 to 271.0)148.4 (107.9 to 204.1)
Serotype 6B1956.9 (1575.3 to 2431.0)1148.1 (889.0 to 1482.6)
Serotype 7F2250.8 (1889.3 to 2681.5)1751.8 (1422.4 to 2157.6)
Serotype 9V1472.3 (1190.9 to 1820.2)1017.6 (790.8 to 1309.4)
Serotype 142106.8 (1689.6 to 2627.0)1945.0 (1572.9 to 2405.1)
Serotype 18C2101.9 (1732.6 to 2550.0)1587.1 (1259.1 to 2000.5)
Serotype 19A1785.8 (1506.1 to 2117.6)1425.9 (1164.7 to 1745.8)
Serotype 19F1051.0 (862.1 to 1281.3)627.2 (490.5 to 802.2)
Serotype 23F1155.6 (867.2 to 1539.9)716.9 (521.1 to 986.3)
SecondaryGeometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F at Week 8

Vaccine-induced functional antibodies were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.

Time frame:
Week 8
Reported as:
Geometric mean · Titer
Geometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F at Week 8
TiterGroup 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23
Serotype 1100.7 (50.5 to 200.9)54.7 (27.5 to 108.5)
Serotype 352.8 (32.2 to 86.5)27.8 (16.6 to 46.5)
Serotype 41075.7 (671.4 to 1723.5)1051.0 (696.0 to 1587.0)
Serotype 5350.5 (193.2 to 636.1)143.9 (77.7 to 266.3)
Serotype 6A3945.3 (2301.9 to 6762.2)4024.1 (2622.8 to 6174.1)
Serotype 6B2154.2 (1325.4 to 3501.3)1259.7 (707.3 to 2243.5)
Serotype 7F3830.5 (2654.6 to 5527.2)2064.0 (1287.4 to 3309.0)
Serotype 9V1555.6 (988.7 to 2447.6)1606.5 (1064.5 to 2424.6)
Serotype 142417.0 (1547.8 to 3774.1)1586.4 (901.6 to 2791.3)
Serotype 18C1890.8 (1313.3 to 2722.1)1563.7 (857.8 to 2850.3)
Serotype 19A2102.3 (1567.6 to 2819.5)1819.8 (1300.2 to 2547.0)
Serotype 19F1039.4 (646.0 to 1672.2)640.4 (378.1 to 1084.9)
Serotype 22F116.4 (54.9 to 246.8)30.9 (16.6 to 57.5)
Serotype 23F1245.8 (656.9 to 2362.5)779.8 (414.3 to 1467.8)
Serotype 33F1515.4 (914.3 to 2511.5)1984.0 (1207.9 to 3259.0)
SecondaryGeometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F at Week 26

Vaccine-induced functional antibodies were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.

Time frame:
Week 26
Reported as:
Geometric mean · Titer
Geometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F at Week 26
TiterGroup 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23
Serotype 139.7 (20.4 to 77.4)18.9 (10.7 to 33.3)
Serotype 319.6 (12.0 to 32.1)9.2 (6.2 to 13.7)
Serotype 4737.1 (451.9 to 1202.1)788.4 (535.3 to 1161.1)
Serotype 5114.4 (58.5 to 223.4)65.6 (36.2 to 118.8)
Serotype 6A1843.2 (1111.0 to 3057.8)1152.9 (655.0 to 2029.3)
Serotype 6B1157.0 (639.0 to 2094.7)1125.1 (689.7 to 1835.6)
Serotype 7F1204.9 (832.1 to 1744.8)770.7 (499.5 to 1189.2)
Serotype 9V698.2 (437.7 to 1113.8)806.5 (500.9 to 1298.7)
Serotype 141458.2 (949.2 to 2240.1)1373.9 (879.5 to 2146.1)
Serotype 18C914.2 (594.3 to 1406.2)691.1 (383.1 to 1246.7)
Serotype 19A1024.3 (749.4 to 1400.1)806.3 (539.3 to 1205.6)
Serotype 19F563.7 (344.0 to 923.7)228.9 (126.1 to 415.5)
Serotype 22F1228.3 (733.3 to 2057.4)45.2 (23.5 to 86.7)
Serotype 23F653.8 (315.8 to 1353.4)366.6 (195.9 to 685.9)
Serotype 33F4672.8 (2968.8 to 7354.7)1151.4 (660.4 to 2007.6)
SecondaryGeometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F at Week 30

Vaccine-induced functional antibodies were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.

Time frame:
Week 30
Reported as:
Geometric mean · Titer
Geometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F at Week 30
TiterGroup 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23
Serotype 136.0 (23.2 to 55.9)43.4 (28.8 to 65.5)
Serotype 313.9 (10.2 to 18.9)32.8 (23.8 to 45.2)
Serotype 4803.6 (601.2 to 1074.2)1060.0 (796.2 to 1411.3)
Serotype 581.5 (51.1 to 130.0)117.3 (83.5 to 164.9)
Serotype 6A1673.9 (1141.5 to 2454.5)1782.7 (1255.1 to 2532.1)
Serotype 6B1330.3 (911.8 to 1940.8)1343.6 (993.3 to 1817.3)
Serotype 7F877.7 (683.3 to 1127.5)1248.4 (955.3 to 1631.4)
Serotype 9V628.9 (444.3 to 890.4)1134.8 (841.4 to 1530.5)
Serotype 141762.9 (1257.3 to 2471.7)1963.3 (1441.9 to 2673.4)
Serotype 18C779.3 (582.9 to 1041.8)1125.6 (843.5 to 1502.1)
Serotype 19A845.5 (649.5 to 1100.6)1256.1 (1027.9 to 1535.0)
Serotype 19F349.1 (236.9 to 514.5)880.8 (663.9 to 1168.6)
Serotype 22F1124.7 (751.7 to 1682.9)982.1 (642.6 to 1501.0)
Serotype 23F574.3 (367.6 to 897.2)755.6 (521.6 to 1094.4)
Serotype 33F5917.9 (4199.6 to 8339.4)7853.5 (5521.3 to 11171.0)

Adverse events

Collected over Up to 30 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo1/200 (0.5%)9/200 (4.5%)177/200 (88.5%)
Group 2: Prevnar 13™ → Placebo → Pneumovax™ 230/200 (0%)11/200 (5.5%)165/200 (82.5%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventGroup 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23
Myocardial infarctionCardiac disorders2/2000/200
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2002/200
Cerebrovascular accidentNervous system disorders0/2002/200
Angina pectorisCardiac disorders1/2000/200
Atrial fibrillationCardiac disorders1/2000/200
Coronary artery diseaseCardiac disorders1/2000/200
PancreatitisGastrointestinal disorders0/2001/200
PneumoniaInfections and infestations0/2001/200
Gastrointestinal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2001/200
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2001/200
Most frequent other events
Most frequent other events
EventGroup 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23
Injection site painGeneral disorders168/200151/200
MyalgiaMusculoskeletal and connective tissue disorders123/200115/200
Injection site swellingGeneral disorders111/20078/200
FatigueGeneral disorders100/20089/200
Injection site erythemaGeneral disorders99/20072/200
HeadacheNervous system disorders78/20060/200
ArthralgiaMusculoskeletal and connective tissue disorders58/20055/200

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Group 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23Total
Mean64.1 ± 8.664.2 ± 8.964.2 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23Total
Female112107219
Male8893181
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23Total
Hispanic or Latino403575
Not Hispanic or Latino158164322
Unknown or Not Reported213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: Prevnar 13™ → Pneumovax™ 23 → PlaceboGroup 2: Prevnar 13™ → Placebo → Pneumovax™ 23Total
American Indian or Alaska Native134
Asian224
Native Hawaiian or Other Pacific Islander011
Black or African American142337
White176163339
More than one race7815
Unknown or Not Reported000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Buchwald UK, Andrews CP, Ervin J, Peterson JT, Tamms GM, Krupa D, Ajiboye P, Roalfe L, Krick AL, Sterling TM, Wang M, Martin JC, Stek JE, Kohn MA, Folaranmi T, Abeygunawardana C, Hartzel J, Musey LK; V110-029 Study Group. Sequential administration of Prevnar 13 and PNEUMOVAX 23 in healthy participants 50 years of age and older. Hum Vaccin Immunother. 2021 Aug 3;17(8):2678-2690. doi: 10.1080/21645515.2021.1888621. Epub 2021 May 21. PubMed 34019468 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Jul 2015, 10 months.

Results were first posted in Feb 2020, 4 years 6 months after primary completion. A results delay was requested in Jun 2016.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 10 months is below that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2014
First posted
Aug 26, 2014
StartActual
Aug 28, 2014
Primary completionActual
Jul 6, 2015
CompletionActual
Jul 6, 2015
Results delay requested
Jun 16, 2016
Results first posted
Feb 5, 2020
Last update
Nov 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02225587
Responsible party
Sponsor
First posted
Aug 26, 2014
Start date
Aug 28, 2014
Primary completion
Jul 6, 2015
Completion
Jul 6, 2015
Results posted
Feb 5, 2020
Last update
Nov 2, 2021

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 13-valent pneumococcal vaccine · 23-valent pneumococcal capsular polysaccharide vaccine

Start the discussion